A Day in the Life of Patients with Developmental and Epileptic Encephalopathies (DEEs) and Their Caregivers: Opportunities for Active Participation in the Transition of Care and Long-Term Disease Management
FACULTY
Kelly G. Knupp, MD
Professor, Pediatrics-Neurology
University of Colorado School of Medicine
Children’s Hospital Colorado Anschutz Medical Campus
Aurora, CO
FeaturingÂ
Hilary Rayburn and Olivia Blevins
Aurora, CO
PROGRAM OVERVIEW
This unique educational program is designed to increase the target audience’s ability to provide a timely and accurate DEE diagnosis, utilize evidence-based, multidisciplinary best practices for disease management, and empower patients with DEEs and their caregivers to actively participate in the treatment journey which will improve the pediatric-to-adult transition of care and long-term outcomes.
TARGET AUDIENCE
This activity is intended to meet the educational needs of epileptologists, pediatric and adult neurologists, and the multidisciplinary team (MDT) of healthcare providers (HCPs) including physician assistants, nurse practitioners, primary care and long-term care (LTC) nurses with a role in providing care of patients with developmental and epileptic encephalopathies (DEEs), including Lennox–Gastaut Syndrome (LGS), Dravet Syndrome (DS), and tuberous sclerosis complex (TSC).
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Recognize pediatric patients in need of initial DEE genetic screening and adult patients for DEE reassessment and employ diagnostic best practices to reduce diagnostic and treatment delays for patients with DEEs
- Utilize evidence-based DEE treatment approaches based on clinical efficacy and safety and practical use characteristics and provide holistic disease management including improvements in non-seizure and quality of life (QoL) outcomes
- Implement collaborative multidisciplinary teamwork and incorporate the patient’s and caregiver’s perspectives through shared decision making (SDM) to optimize the transition of care and long-term outcomes for patients with DEEs
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Kelly G. Knupp, MD | Has received consulting fees from Stoke, Encoded, Biocodex, Longboard; Has received research funds from UCB, Stoke, Eisai; Serves on the Data Safety Monitoring Board for Jazz pharmaceuticals, Epygenix. |
| Hilary Rayburn | Has nothing to disclose. |
| Olivia Blevins | Has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- Michael Milano, MD, has nothing to disclose.
- Deb Gordon, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Andi Koral, Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation & Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASED DATE: December 06, 2024
EXPIRATION DATE: December 06, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Julie Nelson, MD
Assistant Professor, Pediatrics-Neurology
University of Colorado School of Medicine
Children’s Hospital Colorado Anschutz Medical Campus
Aurora, CO
Featuring
The Balkin Family:
Aaron, Hannah, Olivia and Scarlett
Firestone, CO
PROGRAM OVERVIEW
This unique educational program is designed to increase the target audience’s ability to provide a timely and accurate DEE diagnosis, utilize evidence-based, multidisciplinary best practices for disease management, and empower patients with DEEs and their caregivers to actively participate in the treatment journey which will improve the pediatric-to-adult transition of care and long-term outcomes.
TARGET AUDIENCE
This activity is intended to meet the educational needs of epileptologists, pediatric and adult neurologists, and the multidisciplinary team (MDT) of healthcare providers (HCPs) including physician assistants, nurse practitioners, primary care and long-term care (LTC) nurses with a role in providing care of patients with developmental and epileptic encephalopathies (DEEs), including Lennox–Gastaut Syndrome (LGS), Dravet Syndrome (DS), and tuberous sclerosis complex (TSC).
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Recognize pediatric patients in need of initial DEE genetic screening and adult patients for DEE reassessment and employ diagnostic best practices to reduce diagnostic and treatment delays for patients with DEEs
- Utilize evidence-based DEE treatment approaches based on clinical efficacy and safety and practical use characteristics and provide holistic disease management including improvements in non-seizure and quality of life (QoL) outcomes
- Implement collaborative multidisciplinary teamwork and incorporate the patient’s and caregiver’s perspectives through shared decision making (SDM) to optimize the transition of care and long-term outcomes for patients with DEEs
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Julie Nelson, MD | Has nothing to disclose. |
| Aaron Balkin | Has nothing to disclose. |
| Hannah Balkin | Has nothing to disclose. |
| Olivia Balkin | Has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- Michael Milano, MD, has nothing to disclose.
- Deb Gordon, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Andi Koral, Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation & Outcomes Manager for Med Learning Group, has nothing to disclose.Â
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.Â
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. Â
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.Â
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASED DATE: December 06, 2024
EXPIRATION DATE: December 06, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
